FDA will conduct more review of Eli Lilly’s Alzheimer’s drug donanemab – The Washington Post – The Washington Post

The U.S. Food and Drug Administration delayed regulatory action on an experimental Alzheimers drug that was widely expected to be approved this month, drugmaker Eli Lilly said Friday, citing a need f… [read more]

Leave a Reply

Your email address will not be published. Required fields are marked *